14.01.2013 - Danish Bavarian Nordic A/S has announced the consolidation of its manufacturing activities at company headquarters in Kvistgaard.
With the aim of optimising productivity and profitability, all batches for clinical trials will be manufactured in Denmark, as well as the company’s prostate cancer vaccine PROSTVAC®. As a consequence, Bavarian Nordic will close its operations in Berlin, Germany where it has been producing clinical trial material for its MVA-BN based vaccine candidates.
The company said it is seeking to further improve the profitability of the current and future expected contracts with the U.S. Government to manufacture and deliver it MVA-BN-based smallpox vaccine IMVAMUNE®. Bavarian Nordic is currently in an argument with the US government Denmark's biggest drugmaker accuses its customer not to fulfil the conditions of a 2007 contract worth US$500m. Last November, however, the US government signed two new contracts with the company. The restructuring of its production allows Bavarian Nordic a more flexible manufacturing approach and reduces dependence on subcontractors, thus providing the company full control of pre-launch activities for PROSTVAC®. At the Kvistgaard facility, functions to support the production development of PROSTVAC® are already in place and the preparatory work thus requires only modest investments.
16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.
14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.
31.03.2015 In its aim to expand its drug portfolio in orphan disease products, Horizon Pharma has acquired US company Hyperion Therapeutics for US$1.1bn in cash. The takeover entitles the UK biopharma to all of Hyperion’s common stock.
31.03.2015 Merck Serono has forged a US$941m (€876m) deal with US Intrexon for the development and commercialisation of CAR-T therapies. The new CAR-T projects are set to strengthen their R&D technology portfolio in immuno-oncology.